Clinical data | |
---|---|
Trade names | Oxarol |
Other names | 22-Oxacalcitriol; OCT |
Routes of administration | IV or topical |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.212.050 |
Chemical and physical data | |
Formula | C26H42O4 |
Molar mass | 418.618 g·mol−1 |
3D model ( JSmol) | |
| |
|
Maxacalcitol (trade name Oxarol) is a vitamin D3 analog and vitamin D receptor activator (VDRA). [1] As a pharmaceutical drug, it is used as an injection to treat secondary hyperparathyroidism resulting from hemodialysis and as a topical ointment for psoriasis. [2]
It was approved for use in Japan in 2010 [3] and in Taiwan in 2018. [4]
Clinical data | |
---|---|
Trade names | Oxarol |
Other names | 22-Oxacalcitriol; OCT |
Routes of administration | IV or topical |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.212.050 |
Chemical and physical data | |
Formula | C26H42O4 |
Molar mass | 418.618 g·mol−1 |
3D model ( JSmol) | |
| |
|
Maxacalcitol (trade name Oxarol) is a vitamin D3 analog and vitamin D receptor activator (VDRA). [1] As a pharmaceutical drug, it is used as an injection to treat secondary hyperparathyroidism resulting from hemodialysis and as a topical ointment for psoriasis. [2]
It was approved for use in Japan in 2010 [3] and in Taiwan in 2018. [4]